Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2017.0264
PERSPECTIVE
|
Predicting risk of disease and therapeutic resistance for patients with Hepatocellular Carcinoma.
|
Demosthenes Ziogas, MD, PhD 1, 2.
|
Affiliation: Demosthenes Ziogas MD, PhD,
1Department of Surgery, 'G. Hatzikosta' General Hospital, Ioannina 45001, Greece
2Centre for Biosystems and Synthetic Genomic Network Medicine Center – CBS.GenNetMed Ioannina University, Ioannina, Greece.
E-mail: deziogas@hotmail.com
|
Abstract
Multiple negative phase II randomized controlled trials (RCTs) fail to prove a significant overall survival on evaluating the new targeted drugs and do not gain FDA approval. Conventional drug discovery strategy is associated with high costs of millions US dollars for pharmaceutical industry, adverse of patients in these trials receiving the experimental agent and lose long time for ineffective research towards an error of investigational direction.
In contrast to Biankin et al. in which drug effective prediction strategy has included both no biomarker and biomarker-directed agent, this opinion article is focused only on biomarker-directed drug development. This new concept can allow higher predictivity of the expected agent. Moreover, our concept is also focused on drug development based rational prospective clinico-genomic trials for the discovery of novel therapeutic targets.
(Citation: Gastric & Breast Cancer 2017; 12(2): 91-98)
|
|
| You can have an online full-text access and a PDF of this article: |
- Either purchase this paper for €35 EUR. Please, click here
|
|
- Or through one year subscription PayPal
|
|
Online
ISSN : 1109 - 7647
Print ISSN : 1109 - 7655
 We
subscribe to the HONcode principles. Verify
here.
please, read our policy about privacy
and confidentiality of information and transparency
of sponsorship
last
update: 31 August 2017 |
|
